newsfilter
← Latest News
GlobeNewswire·

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO -- REDWOOD CITY, Calif., June 07, 2021 (GLO